Abstract: The present invention provides a novel compound having an excellent antitumor effect. The compound of the present invention is represented by the following general formula (1) wherein R1 and R2 are aryl or the like; A is lower alkylene; Ring X is optionally substituted arylene; E is bond or lower alkenylene; Ring Y is optionally substituted heterocycloalkylene containing one or more nitrogen atoms, one of which is attached to the adjacent carbonyl group; G is —NH-G2-, —N(lower alkyl)-G2-, —NH—CH2-G2-, —N(lower alkyl)-CH2-G2- or —CH2-G2-, [wherein G2 binds to R2, G2-R2 is bond-R2, phenylene-G3-R2, phenylene-G4-O—R2, phenylene-G5-NH—R2, phenylene-G6-N(lower alkyl)-R2 or quinolinediyl-O—R2, the phenylene of said phenylene-containing groups being optionally substituted with one or more substituents; G3-R2 is —O-lower alkylene-R2 or the like; G4-O— is lower alkylene-O— or the like; G5 is lower alkylene; G6 is lower alkylene].

Abstract: The present invention provides a heterocyclic compound represented by General Formula (1): wherein R1 is a group R5—Z1—, etc., Z1 is a lower alkylene group, etc., and R5 is a group represented by General Formula; wherein R13 is a hydrogen atom, etc., m is an integer from 1 to 5; R2 is a hydrogen atom: Y is CH or N: A1 is a heterocyclic ring selected from the group consisting of indolediyl groups, wherein the heterocyclic ring may have at least one substituent: T is a group —CO—, etc.: R3 is a hydrogen atom, etc.: R4 is a lower alkyl group optionally substituted by one or more hydroxy groups, etc.: R3 and R4, together with the nitrogen atom to which they bind, may bind to each other and form a 5- to 10-membered saturated heterocyclic ring, wherein the heterocyclic ring may have at least one substituent. The heterocyclic compound of the present invention has excellent effects of suppressing the production of collagen and/or treating tumors.

Abstract: The present invention provides a STAT3/5 activation inhibitor containing an aromatic compound represented by the general formula or a salt thereof as an active ingredient: Wherein X1 represents a nitrogen atom or a group —CH?, R1 represents a group —Z—R6, in which Z represents a group —CO—, a group —CH(OH)— or the like, R6 represents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R2 represents a hydrogen atom or a halogen atom, Y represents a group —O—, a group —CO—, a group —CH(OH)— or a lower alkylene group, and A represents a group

Abstract: The present invention provides a novel compound having an excellent antitumor effect. The compound of the present invention is represented by the following general formula (1) wherein R1 and R2 are aryl or the like; A is lower alkylene; Ring X is optionally substituted arylene; E is bond or lower alkenylene; Ring Y is optionally substituted heterocycloalkylene containing one or more nitrogen atoms, one of which is attached to the adjacent carbonyl group; G is —NH-G2-, —N(lower alkyl)-G2-, —NH—CH2-G2-, —N(lower alkyl)-CH2-G2- or —CH2-G2-, [wherein G2 binds to R2, G2-R2 is bond-R2, phenylene-G3-R2, phenylene-G4-O—R2, phenylene-G5-NH—R2, phenylene-G6-N(lower alkyl)-R2 or quinolinediyl-O—R2, the phenylene of said phenylene-containing groups being optionally substituted with one or more substituents; G3-R2 is —O-lower alkylene-R2 or the like; G4-O— is lower alkylene-O— or the like; G5 is lower alkylene; G6 is lower alkylene].

Abstract: An object of the present invention is to provide a STAT3/5 activation inhibitor. The present invention provides a STAT3/5 activation inhibitor containing an aromatic compound represented by the general formula or a salt thereof as an active ingredient: wherein X1 represents a nitrogen atom or a group —CH?, R1 represents a group —Z—R6, in which Z represents a group —CO—, a group —CH(OH)— or the like, R6 represents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R2 represents a hydrogen atom or a halogen atom, Y represents a group —O—, a group —CO—, a group —CH(OH)— or a lower alkylene group, and A represents a group wherein R3 represents a hydrogen atom, a lower alkoxy group or the like, p represents 1 or 2, R4 represents an imidazolyl lower alkyl group or the like.

Abstract: An object of the present invention is to provide a nucleic acid delivery carrier composition of low toxicity and high safety, the carrier composition, when used to administer a nucleic acid such as an siRNA into an animal-derived cell or organism, being capable of delivering efficiently the nucleic acids into the cells while protecting it from being degraded; and a nucleic acid deliver composition containing the carrier and a nucleic acid. The carrier composition for delivery of a nucleic acid is prepared by mixing (A) a cationic lipid having a steroid skeleton with (B) a tertiary ammonium salt-type cationic lipid. The nucleic acid delivery composition is prepared by mixing the nucleic acid delivery carrier with a nucleic acid.

Abstract: The present invention provides a useful and highly safe agent for the treatment of chronic obstructive pulmonary disease, which contains, as the effective ingredient, at least one compound selected from the group consisting of thiazole derivatives and salts thereof represented by the general formula (1), wherein, R1 is a phenyl group which may have 1 to 3 lower alkoxy groups as the substituents on the phenyl ring; R2 is a pyridyl group which may have 1 to 3 carboxyl groups as the substituents on the pyridine ring.

Abstract: The present invention provides a heterocyclic compound represented by General Formula (1): wherein R1 is a group R5—Z1—, etc., Z1 is a lower alkylene group, etc., and R5 is a group represented by General Formula; wherein R13 is a hydrogen atom, etc., m is an integer from 1 to 5; R2 is a hydrogen atom: Y is CH or N: A1 is a heterocyclic ring selected from the group consisting of indolediyl groups, wherein the heterocyclic ring may have at least one substituent: T is a group —CO—, etc.: R3 is a hydrogen atom, etc.: R4 is a lower alkyl group optionally substituted by one or more hydroxy groups, etc.: R3 and R4, together with the nitrogen atom to which they bind, may bind to each other and form a 5- to 10-membered saturated heterocyclic ring, wherein the heterocyclic ring may have at least one substituent. The heterocyclic compound of the present invention has excellent effects of suppressing the production of collagen and/or treating tumors.

Abstract: An object of the present invention is to provide a STAT3/5 activation inhibitor. The present invention provides a STAT3/5 activation inhibitor containing an aromatic compound represented by the general formula or a salt thereof as an active ingredient: wherein X1 represents a nitrogen atom or a group —CH?, R1 represents a group —Z—R6, in which Z represents a group —CO—, a group —CH(OH)— or the like, R6 represents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R2 represents a hydrogen atom or a halogen atom, Y represents a group —O—, a group —CO—, a group —CH(OH)— or a lower alkylene group, and A represents a group wherein R3 represents a hydrogen atom, a lower alkoxy group or the like, p represents 1 or 2, R4 represents an imidazolyl lower alkyl group or the like.

Abstract: An object of the present invention is to provide a nucleic acid delivery carrier composition of low toxicity and high safety, the carrier composition, when used to administer a nucleic acid such as an siRNA into an animal-derived cell or organism, being capable of delivering efficiently the nucleic acids into the cells while protecting it from being degraded; and a nucleic acid deliver composition containing the carrier and a nucleic acid. The carrier composition for delivery of a nucleic acid is prepared by mixing (A) a cationic lipid having a steroid skeleton with (B) a tertiary ammonium salt-type cationic lipid. The nucleic acid delivery composition is prepared by mixing the nucleic acid delivery carrier with a nucleic acid.

Abstract: The present invention provides a useful and highly safe agent for the treatment of chronic obstructive pulmonary disease, which contains, as the effective ingredient, at least one compound selected from the group consisting of thiazole derivatives and salts thereof represented by the general formula (1), wherein, R1 is a phenyl group which may have 1 to 3 lower alkoxy groups as the substituents on the phenyl ring; R2 is a pyridyl group which may have 1 to 3 carboxyl groups as the substituents on the pyridine ring.

Abstract: The present invention provides a useful and highly safe agent for curing chronic obstructive pulmonary disease, which contains, as the effective ingredient, at least one compound selected from the group consisting of thiazole derivatives and salts thereof represented by the general formula (1), 1

Abstract: The invention relates to (1) a cosmetic material comprising silica-coated metal oxide particles further surface-treated with a hydrophobicizing agent, and (2) metal oxide particles having a specified infrared absorption spectrum intensity ratio and refractive index which are further treated with a hydrophobicizing agent, and to a process for their production. The invention further relates to a silica-coated metal oxide sol which gives such particles, and to a process for its production. The invention can give ultraviolet-screening cosmetic materials with an excellent transparent feel, wherein the particles are satisfactorily dispersed.

Abstract: The present invention provides homogeneously surface-fluorinated metal oxide particulates, characterized in that a metal oxide particulate such as Ti, Al, Si, Ag, Cu, Fe, Zr, Ce, Mn, Sn, Ge and Ta is surface reacted with fluorine gas while allowing the metal oxide particulate to flow, and also provides a process for manufacturing the metal oxide particulates. The homogeneously surface-fluorinated metal oxide particulates according to the present invention are useful as an additive for a weatherproof coating material, a weatherproof resin or a cosmetic material. Furthermore, according to the process of the present invention, the surface of a metal oxide particulate can be homogeneously fluorinated at any ratio in a very simple and efficient manner.

Abstract: Cosmetics comprising silica-coated metal oxide powder having a thickness of the silica coating of 0.1 to 100 nm, and a photocatalytic activity as measured by tetralin auto-oxidation method of 6 mmH2O/min or less. Silica-coated metal oxide powder coated with a silica coating having an absorption peak intensity ratio I (I=I1/I2, wherein I1 is an absorption peak intensity at 1,150 to 1,250 cm−1 and I2 is an absorption peak intensity at 1,000 to 1,100 cm−1) between the infrared absorption spectra in the region of 1,150 to 1,250 cm−1 and the region of 1,000 to 1,100 cm−1 of 0.2 or more, and having a refractive index of 1.435 or more.

Abstract: A pressure switch comprises an electrically conductive housing, a stationary contact stationarily installed in the housing and a movable contact movably received in the housing. The movable contact is movable to contact with the stationary contact. A hydraulically operated moving device is employed for moving the movable contact in accordance with a hydraulic pressure applied thereto. The stationary contact is formed with a blind bore. An end piece to which an end of an electric cable has been connected is press-fitted in the blind bore.

Abstract: Water-soluble microcapsules using a water-containing hydrophilic substance as a core material and at least one member selected from the group consisting of polyvinyl alcohol and modified polyvinyl alcohols as a coating material are stably retained in a concentrated aqeuous solution and are dissolved in water or a dilute aqueous solution.

Abstract: Ethyl acetate and an excess of ethylene glycol monoethyl ether are subjected to ester-interchange reaction at a temperature not exceeding 100.degree. C. in the presence of a strongly acidic cation exchange resin as a catalyst. The resulting reaction mixture is distilled to recover the ethylene glycol monoethyl ether acetate formed. The unchanged reactants are recycled to the reaction zone for re-use, and the by-product ethanol is recovered in a highly pure form. This method can be continuously performed easily and effectively without the need to separate the catalyst or to employ complex distilling steps and without involving other difficulties.

Abstract: A grommet is disclosed, which grommet comprises a female member of a U-shaped end face containing a U groove for accommodating a stretched cord and provided at one extremity of said U groove with an elevated wall rising from the bottom of said groove and at the other extremity with a projecting wall extending inwardly from one side wall and a male member adapted to fit the U groove of the female member for fast engagement therewith, whereby the engagement of the male and female members gives rise to a laterally elongate opening on the side incorporating said elevated wall and a longitudinally elongate opening on the side incorporating the projecting wall. When the male and female members are brought into mutual engagement with a cord interposed therebetween, the cord is fastened in position in its twisted state within the grommet.